Fresh analysis reveals that people who come off popular GLP-1 drugs like semaglutide or tirzepatide can put back on shed pounds at a significantly accelerated pace than those who halt conventional lifestyle programs.
Findings released in a leading health publication points out that while obese individuals frequently drop a large proportion of their body weight while using the jabs, the weight returns at an average rate of 0.8 kg per month once they quit.
"Individuals purchasing such medications must be cognizant of the danger of rapid weight regain when the medication is stopped," warns researcher Dr. Susan Jebb.
That rate of recovery means a return to original mass within about a year and a half.
Analyzing Therapies
The analysis, which looked at dozens of trials involving thousands of patients, compared the results of GLP-1 agonists with older methods.
Researchers emphasize that people who shed pounds through diet and exercise generally have a slower weight regain—approximately 100 grams monthly—once they finish.
Explaining the Rapid Rebound
Experts believe the mechanism of the jabs is key to understanding the heightened weight return.
The injections imitate a natural hormone called GLP-1, which helps regulate hunger.
"Sustained high doses of GLP-1 levels far above than the body's typical production could lead to the system to generate a reduced amount of its own natural GLP-1, and may also lessen sensitivity to its effects," noted Dr. Adam Collins, a nutrition specialist.
"Stopping of this hormone supplement leads to hunger is no longer kept in check, making excessive eating a significant risk."
A Chronic Issue?
Health authorities advise the injections for people with obesity-related health risks, accompanied by recommended diet and exercise modifications.
Many experts contend that, given the high risk of relapse, the therapy is often life-long.
This opinion is supported by pharmaceutical companies, who state that the results "highlight the long-term nature of obesity," similar to managing conditions like diabetes.
Patient Experiences
People who have discontinued the jabs explain a intense resurgence of hunger.
"I experienced a trigger that goes on and I was suddenly starving," recalled one woman.
The struggle is compounded if individuals have not established permanent lifestyle or habit modifications during therapy.
Growing Adoption
Survey data show that millions of people in the UK have used these injections in the past year, with interest continuing to grow.
- Use is greater among women compared to men.
- The middle-aged demographic shows the highest usage rates.
- Many obtain the drugs through private prescriptions rather than public health services.
In conclusion, experts caution that while GLP-1 drugs are powerful agents for shedding pounds, they are not a magic cure and long-term success relies on ongoing behavioural support.
